FDA approves Eli Lilly's once-weekly insulin Onswik for type 2 diabetes

The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, providing an alternative to daily injections. This marks a significant product differentiation in the insulin market, potentially shifting patient preference and competitive dynamics. The approval is confirmed by the FDA action, though market uptake and payer coverage remain uncertain.